Quadrant Capital Group LLC Zai Lab LTD Transaction History

Quadrant Capital Group LLC

$1.42 Billion
Q3 2024

A detailed history of Quadrant Capital Group LLC transactions in Zai Lab LTD stock. As of the latest transaction made, Quadrant Capital Group LLC holds 31 shares of ZLAB stock, worth $796. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 31 -0.0%

Holding current value

$796

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$13.72 - $21.55 $425 - $668	31 New	31 $0
Q4 2023 Feb 08, 2024	SELL	$22.97 - $30.58 $390 - $519	-17 Reduced 19.54%	70 $1,000
Q3 2023 Nov 14, 2023	BUY	$22.72 - $31.49 $159 - $220	7 Added 8.75%	87 $2,000
Q1 2023 May 11, 2023	BUY	$30.21 - $48.1 $453 - $721	15 Added 23.08%	80 $2,000
Q4 2022 Feb 10, 2023	SELL	$22.28 - $38.71 $1,203 - $2,090	-54 Reduced 45.38%	65 $1,000
Q3 2022 Nov 10, 2022	BUY	$34.2 - $51.69 $3,693 - $5,582	108 Added 981.82%	119 $4,000
Q2 2022 Aug 09, 2022	SELL	$23.14 - $49.68 $3,424 - $7,352	-148 Reduced 93.08%	11 $0
Q1 2022 May 06, 2022	SELL	$27.77 - $64.4 $28,853 - $66,911	-1,039 Reduced 86.73%	159 $7,000
Q4 2021 Feb 01, 2022	BUY	$54.9 - $105.21 $22,179 - $42,504	404 Added 50.88%	1,198 $75,000
Q3 2021 Nov 12, 2021	SELL	$105.0 - $178.37 $1,995 - $3,389	-19 Reduced 2.34%	794 $84,000
Q2 2021 Aug 09, 2021	BUY	$125.11 - $180.0 $27,774 - $39,960	222 Added 37.56%	813 $144,000
Q1 2021 May 12, 2021	BUY	$126.27 - $191.71 $10,985 - $16,678	87 Added 17.26%	591 $79,000
Q4 2020 Feb 16, 2021	BUY	$81.94 - $135.34 $3,359 - $5,548	41 Added 8.86%	504 $68,000
Q3 2020 Nov 13, 2020	BUY	$73.3 - $89.48 $24,262 - $29,617	331 Added 250.76%	463 $39,000
Q2 2020 Aug 13, 2020	BUY	$48.82 - $82.53 $6,444 - $10,893	132 New	132 $11,000

Others Institutions Holding ZLAB

# of Institutions

121

Shares Held

46.7M

Call Options Held

223K

Put Options Held

588K

View Full List

About Zai Lab Ltd

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.52B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

More about ZLAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.

Account

Quadrant Capital Group LLC Zai Lab LTD Transaction History